Jasmine I. Rizzo

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2019 · 3.7K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

F. Stephen Hodi, Vanna Chiarion‐Sileni, René González et al. · The Lancet Oncology · 2018 · 1.4K citations

Life Sciences, Immunology, Oncology +16

Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy

Paolo A. Ascierto, Georgina V. Long, Caroline Robert et al. · JAMA Oncology · 2018 · 345 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma

F. Stephen Hodi, Jedd D. Wolchok, Dirk Schadendorf et al. · Cancer Immunology Research · 2021 · 137 citations · Full text

Life Sciences, Immunology, Oncology +17

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

Hussein A. Tawbi, Peter Forsyth, F. Stephen Hodi et al. · Neuro-Oncology · 2021 · 125 citations · Full text

Medicine, Oncology, Pharmacotherapy +16